Key Points
- CFO James Edgemond sold 21,000 shares on Dec. 8 at an average of $478.60 and completed five prior 21,000‑share sales in Nov–Dec, representing roughly $58.6 million across six transactions and reducing his stake to 8,142 shares — a 72.06% decrease in ownership.
- Despite the heavy insider selling, United Therapeutics (NASDAQ:UTHR) has a market cap of $20.51 billion and a consensus analyst rating of Moderate Buy with a consensus price target of $505, and several brokers have recently raised targets into the $587–$600 range.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CFO James Edgemond sold 21,000 shares of the business's stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $478.60, for a total transaction of $10,050,600.00. Following the completion of the sale, the chief financial officer directly owned 8,142 shares in the company, valued at $3,896,761.20. This trade represents a 72.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
James Edgemond also recently made the following trade(s):
- On Monday, December 1st, James Edgemond sold 21,000 shares of United Therapeutics stock. The shares were sold at an average price of $479.99, for a total transaction of $10,079,790.00.
- On Monday, November 24th, James Edgemond sold 21,000 shares of United Therapeutics stock. The shares were sold at an average price of $473.64, for a total value of $9,946,440.00.
- On Monday, November 17th, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $470.36, for a total value of $9,877,560.00.
- On Monday, November 10th, James Edgemond sold 21,000 shares of United Therapeutics stock. The shares were sold at an average price of $452.07, for a total value of $9,493,470.00.
- On Tuesday, November 4th, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $436.09, for a total value of $9,157,890.00.
United Therapeutics Price Performance
NASDAQ UTHR opened at $476.36 on Wednesday. The company has a market cap of $20.51 billion, a P/E ratio of 18.05, a P/E/G ratio of 4.76 and a beta of 0.86. The stock has a 50-day moving average of $455.16 and a two-hundred day moving average of $371.12. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $492.62.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The business had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. During the same quarter last year, the firm posted $6.39 earnings per share. The business's revenue for the quarter was up 6.8% compared to the same quarter last year. On average, analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.
Institutional Investors Weigh In On United Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. Clearstead Advisors LLC increased its stake in United Therapeutics by 8.9% in the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company's stock valued at $117,000 after purchasing an additional 23 shares during the last quarter. Bessemer Group Inc. grew its position in shares of United Therapeutics by 2.6% in the 3rd quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company's stock valued at $472,000 after buying an additional 28 shares during the last quarter. Archer Investment Corp raised its stake in United Therapeutics by 9.5% during the 3rd quarter. Archer Investment Corp now owns 356 shares of the biotechnology company's stock worth $149,000 after acquiring an additional 31 shares in the last quarter. F m Investments LLC lifted its position in United Therapeutics by 1.3% in the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company's stock valued at $741,000 after acquiring an additional 33 shares during the last quarter. Finally, HB Wealth Management LLC boosted its stake in United Therapeutics by 2.9% in the second quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company's stock valued at $355,000 after acquiring an additional 35 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.
Analysts Set New Price Targets
Several brokerages have recently issued reports on UTHR. Royal Bank Of Canada increased their price objective on United Therapeutics from $569.00 to $587.00 and gave the company an "outperform" rating in a research note on Thursday, October 30th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $575.00 price target on shares of United Therapeutics in a research report on Wednesday, November 19th. UBS Group lifted their price objective on United Therapeutics from $580.00 to $600.00 and gave the company a "buy" rating in a research note on Thursday, November 6th. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research note on Wednesday, October 29th. Finally, Weiss Ratings reaffirmed a "buy (b-)" rating on shares of United Therapeutics in a report on Monday. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $505.00.
View Our Latest Research Report on UTHR
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
